Obsidian Therapeutics, Inc.
OBX
$18.68
-$0.05-0.27%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -13.49% | -16.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.50% | -23.77% | |||
| Operating Income | 7.50% | 23.77% | |||
| Income Before Tax | 3.84% | 21.42% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.84% | 21.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.84% | 21.42% | |||
| EBIT | 7.50% | 23.77% | |||
| EBITDA | 7.32% | 23.97% | |||
| EPS Basic | 38.53% | 38.09% | |||
| Normalized Basic EPS | 38.54% | 38.09% | |||
| EPS Diluted | 38.53% | 38.09% | |||
| Normalized Diluted EPS | 38.54% | 38.09% | |||
| Average Basic Shares Outstanding | 56.45% | 26.79% | |||
| Average Diluted Shares Outstanding | 56.45% | 26.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||